Endothelin-1 vasoactive responses in lambs with pulmonary hypertension and increased pulmonary blood flow

被引:49
作者
Wong, J
Reddy, VM
HendricksMunoz, K
Liddicoat, JR
Gerrets, R
Fineman, JR
机构
[1] UNIV CALIF SAN FRANCISCO, DEPT PEDIAT, SAN FRANCISCO, CA 94143 USA
[2] UNIV CALIF SAN FRANCISCO, DEPT CARDIOTHORAC SURG, SAN FRANCISCO, CA 94143 USA
[3] NYU, DEPT PEDIAT, NEW YORK, NY 10016 USA
来源
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY | 1995年 / 269卷 / 06期
关键词
aortopulmonary septal defects; pulmonary heart defects; vascular endothelium; endothelin receptors;
D O I
10.1152/ajpheart.1995.269.6.H1965
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Increased concentrations of endothelin-1 (ET-1) are found in children with congenital heart diseases that produce increased pulmonary blood flow and pulmonary hypertension, but the role of ET-1 in the pathophysiology of pulmonary hypertension is unclear. Therefore, we investigated ET-1-induced vasoactive responses and ET-1 concentrations in an animal model of pulmonary hypertension and increased pulmonary blood flow. Vascular shunts were placed between the ascending aorta and main pulmonary artery in seven late-gestation fetal sheep. Four weeks after spontaneous delivery, ET-1 increased pulmonary vascular resistance by 29.7 +/- 34.4% (P < 0.05), the ET(b)-receptor agonist [Ala(1,3,11,15)]ET-1 (4AlaET-1) had no effect, and the ET(a)-receptor antagonist cyclo (D-Asp-L-Pro-D-Val-L-Leu-D-Trp) (BQ-123) decreased pulmonary vascular resistance by -16.0 +/- 5.6% (P < 0.05). In contrast, in six control lambs with a similar degree of pulmonary hypertension induced by U-46619, ET-1 and 4AlaET-1 decreased pulmonary vascular resistance by 24.8 +/- 17.6, and 20.0 +/- 13.8%, respectively (P < 0.05). In addition, systemic arterial concentrations of immunoreactive ET-1 were elevated in lambs with pulmonary hypertension (29.2 +/- 9.6 vs. 15.2 +/- 10.7 pg/ml, P < 0.05). Pulmonary hypertension and increased pulmonary blood flow alters the response of ET-1 from pulmonary vasodilation to vasoconstriction. These altered responses suggest a role for ET-1 and its receptors in the pathogenesis of pulmonary hypertension secondary to increased pulmonary blood flow.
引用
收藏
页码:H1965 / H1972
页数:8
相关论文
共 35 条
[31]   Activation of the right ventricular endothelin (ET) system in the monocrotaline model of pulmonary hypertension:: response to chronic ETA receptor blockade [J].
Jasmin, JF ;
Cernacek, P ;
Dupuis, J .
CLINICAL SCIENCE, 2003, 105 (06) :647-653
[32]   Complete results of the first randomized, placebo-controlled study of bosentan, a dual endothelin receptor antagonist, in pulmonary arterial hypertension [J].
Badesch, DB ;
Bodin, F ;
Channick, RN ;
Frost, A ;
Rainisio, M ;
Robbins, IM ;
Roux, S ;
Rubin, LJ ;
Simonneau, G ;
Sitbon, O ;
Tapson, VF .
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2002, 63 (04) :227-246
[33]   Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension - A 1-year follow-up study [J].
Langleben, D ;
Hirsch, AM ;
Shalit, E ;
Lesenko, L ;
Barst, RJ .
CHEST, 2004, 126 (04) :1377-1381
[34]   Endothelin receptor blockade does not affect blood pressure or angiotensin II levels in CYP1A1-Ren-2 transgenic rats with acutely induced hypertension [J].
Vanourkova, Zdenka ;
Kramer, Herbert J. ;
Erbanova, Michaela ;
Baecker, Angela ;
Cervenka, Ludek ;
Huskova, Zuzana ;
Chabova, Vera Certikova ;
Tesar, Vladimir ;
Dvorak, Pavel ;
Maly, Jan ;
Vaneckova, Ivana .
VASCULAR PHARMACOLOGY, 2009, 50 (5-6) :194-199
[35]   Effect of novel mixed ETA/ETB antagonists on responses to ET-1 in human small muscular pulmonary arteries [J].
MacLean, MR ;
Docherty, CC ;
McCulloch, KM ;
Morecroft, I .
PULMONARY PHARMACOLOGY & THERAPEUTICS, 1998, 11 (2-3) :147-149